The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
Plasma-guided adaptive first-line chemoimmunotherapy for non-small cell lung cancer (NSCLC). This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full ...
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
View all available purchase options and get full access to this article. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
A randomized, double-blind, phase III study comparing trifluridine/tipiracil (FTD/TPI) versus placebo in patients with molecular residual disease following curative resection of colorectal cancer (CRC ...
The impact of adherence to NCCN and BCLC treatment guidelines on survival in HCC: A single center study. 10 key areas highlighting differences identified between HICs and LMICs. MDT development ...
Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial. This is an ASCO Meeting Abstract from the 2024 ASCO Annual ...
Tolerability and efficacy of BrECADD versus BEACOPP in advanced stage classical Hodgkin lymphoma: GHSG HD21, a randomized study. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting II.
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced BRAF-V600E/K-mutated melanoma: The primary analysis of an ...
Menopausal hormone therapy and ovarian and endometrial cancers: Long-term follow-up of the Women’s Health Initiative randomized trials. Comparative risk of obesity-related cancer with glucagon-like ...
BCMA-directed CART therapy in patients with multiple myeloma and CNS involvement. Evaluation of cytokine release syndrome (CRS) in patients with relapsed or refractory multiple myeloma (RRMM) ...
Efficacy of immunotherapy in first-line treatment for non-small cell lung cancer with HER2 mutation: Results from LC-SCRUM-Asia. Preliminary results from a FIH, open-label phase 1 study with BMC128, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results